Navigation Links
Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
Date:2/5/2008

in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, risks associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing, and results of our clinical trials, competition, market acceptance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on partners, subcontractors, and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 20-F for the year ended November 30, 2006, as well as in our later public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 29, 2015 According to a new ... by Application (Diagnostics, Therapeutics, R&D), by Technology (SELEX, Other Technologies), ... CRO) - Global Forecast to 2020", published by MarketsandMarkets, the ... 2020 from $107.56 Million in 2015, at a CAGR of ... and 67 F igures spread through 125 ...
(Date:6/29/2015)... NEW YORK , June 29, 2015   For ... of life sciences to assess their overall digital maturity ... to show that these companies are not maturing fast ... the healthcare industry in numerous ways overall and customers ... industries in terms of digital customer engagement.  ...
(Date:6/26/2015)... , June 26, 2015   ... ), a pet therapeutics company focused on ... biopharmaceutical products for companion animals, today announced ... study of capromorelin (AT-002), the company,s innovative ... is a small molecule that mimics ghrelin, ...
(Date:6/26/2015)...  A San Francisco company, Pembient, recently announced it ... horn: beer in China and ... response to the emerging industry, two leading rhino conservation ... synthetic rhino horn.  The International ... International (SRI) released a joint statement ...
Breaking Biology Technology:Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5Rhino Experts Oppose Synthetic Rhino Horn as Solution to Poaching Crisis 2
... , , Multiporator / Electroporator 2510 , , , , , , ... Transformation Protocol , Protocol No. 4308 915.506 12/2001 , , ... , , , Microorganism , ... Cell type , Bacteria, gram negative, ...
... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.538 04/2002 , , , ... , Microorganism , ... Cell type , Bacteria, gram positive, , ...
... , Multiporator / Electroporator 2510 , , , , , , ... Protocol , Protocol No. 4308 915.502 12/2001 , , ... , , Microorganism , ... Cell type , Bacteria, gram negative, , ...
Cached Biology Technology:Borrelia burgdorferi 2Bifidobacterium animalis 2Agrobacterium tumefaciens 2
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical contract manufacturing ... headquartered in Springville, Utah , has announced ... corporation with locations in Santa Clara, CA ... ). This acquisition will incorporate MedConx,s manufacturing facility ... existing facility in Costa Rica , resulting ...
(Date:6/25/2015)...  TAKE Solutions Ltd., a global business technology solutions ... Patent and Trademark Office (USPTO) for its "Method for ... Clinical Accelerators to reduce the time taken to standardize ... without the accelerators), thus reducing time to market. ... the heart of the patented Clinical Data Standardization Process ...
(Date:6/24/2015)... JOSE, Calif. , June 24, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... sensor to provide secure authentication for its latest ... recently reached more than 200 million shipments of ... with Sharp reinforces Synaptics, strength, scalability and leadership ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... the Southern Ocean, large quantities of surface-drifting plankton algae are ... surface waters, which can affect the global carbon dioxide cycle. ... which has just drawn to a close in Cape Town ... Wegener Institute, part of the Helmholtz Association. On February 5, ...
... Rochet, a research scientist at IFREMER (The French Research ... the prestigious Pew Fellowship in Marine Conservation to determine ... to the delicately balanced marine ecosystem. She will use ... use of that technique, and to further improve its ...
... YORK CITY - Dr. Ussif Rashid Sumaila, an Associate ... in Vancouver, Canada, is among five ocean experts to ... Conservation, which supports critical marine conservation projects around the ... the financial factors contributing to unsustainable commercial fishing and ...
Cached Biology News:Antarctic expedition provides new insights into the role of the Southern Ocean for global climate 2Antarctic expedition provides new insights into the role of the Southern Ocean for global climate 3Antarctic expedition provides new insights into the role of the Southern Ocean for global climate 42008 Pew Fellowship in Marine Conservation awarded to Dr. Marie-Joëlle Rochet from IFREMER 22008 Pew Fellowship in Marine Conservation awarded to Dr. Marie-Joëlle Rochet from IFREMER 32008 Pew Fellowship in Marine Conservation awarded to Dr. Marie-Joëlle Rochet from IFREMER 42008 Pew Fellowship in Marine Conservation awarded to Dr. Ussif Rashid Sumaila 22008 Pew Fellowship in Marine Conservation awarded to Dr. Ussif Rashid Sumaila 32008 Pew Fellowship in Marine Conservation awarded to Dr. Ussif Rashid Sumaila 4
... The FDSS6000 System is an imaging ... assay development and high throughput screening ... luminescence modalities., The Hamamatsu light sources ... our companys decades-long experience in photon ...
... supplies, for 10 chips, provides the ... standard-sensitivity RNA analysis (nanogram levels) with ... electrophoresis system. Supplied are 1,250 microliters ... stain, 20 microliters RNA ladder, 900 ...
... White solid. PROTECT FROM LIGHT. PACKAGED ... compound that acts as a selective, ... PTP1B (IC 50 = 4 ... 403 and PTP1B 298 , ...
Anti-NCAPD3 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunoprecipitation, Western Blot...
Biology Products: